Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Santini, Valeria, Almeida, Antonio, Giagounidis, Aristoteles, Gröpper, Stefanie, Jonasova, Anna, Vey, Norbert, Mufti, Ghulam J, Buckstein, Rena, Mittelman, Moshe, Platzbecker, Uwe, Shpilberg, Ofer, Ram, Ron, Del Cañizo, Consuelo, Gattermann, Norbert, Ozawa, Keiya, Risueño, Alberto, MacBeth, Kyle J, Zhong, Jianhua, Séguy, Francis, Hoenekopp, Albert, Beach, C L, Fenaux, Pierre
Published in Journal of clinical oncology (01.09.2016)
Published in Journal of clinical oncology (01.09.2016)
Get full text
Journal Article
P1055: BROMODOMAIN AND EXTRA‐TERMINAL (BET) INHIBITOR INCB057643 (LIMBER‐103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY
Watts, Justin M., Hunter, Anthony M., Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Reeves, Brandi, Vannucchi, Alessandro, Bose, Prithviraj, Ayala Diaz, Rosa, Halpern, Anna B., Chen, Xuejun, Seguy, Francis, Zhou, Feng, Zheng, Fred, Vachhani, Pankit
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P1022: PHASE 1/2 STUDY OF THE ACTIVIN RECEPTOR‐LIKE KINASE 2 (ALK2) INHIBITOR ZILURGISERTIB (INCB000928, LIMBER‐104) AS MONOTHERAPY OR WITH RUXOLITINIB IN PATIENTS WITH ANEMIA DUE TO MYELOFIBROSIS
Bose, Prithviraj, Mohan, Sanjay, Oh, Stephen, Gotlib, Jason, Ritchie, Ellen, Shimomura, Taizo, Ali, Haris, Boyer, Francoise, Guglielmelli, Paola, Hunter, Anthony M., Lamothe, Betty, Cui, Yi, Seguy, Francis, Mcbride, Amanda, Palandri, Francesca, Takeuchi, Masahiro, Kiladjian, Jean‐Jacques
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)
Almeida, Antonio, Santini, Valeria, Gröpper, Stefanie, Jonasova, Anna, Vey, Norbert, Giagounidis, Aristoteles, Hellström-Lindberg, Eva, Mufti, Ghulam J., Sanz, Guillermo, Skikne, Barry, Hoenekopp, Albert, Séguy, Francis, Zhong, Jianhua, Fenaux, Pierre
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Phase I Pharmacological and Bioavailability Study of Oral Diflomotecan (BN80915), a Novel E-Ring-modified Camptothecin Analogue in Adults with Solid Tumors
GELDERBLOM, Hans, SALAZAR, Ramon, PRINCIPE, Paola, TWELVES, Chris, VERWEIJ, Jaap, PENTHEROUDAKIS, George, DE JONGE, Maja J. A, DEVLIN, Martin, VAN HOOIJE, Christel, SEGUY, Francis, OBACH, Rosendo, PRUNONOSA, Joan
Published in Clinical cancer research (15.09.2003)
Get full text
Published in Clinical cancer research (15.09.2003)
Journal Article
Efficacy and Safety of Lenalidomide (LEN) Versus Placebo (PBO) in RBC-Transfusion Dependent (TD) Patients (Pts) with IPSS Low/Intermediate (Int-1)-Risk Myelodysplastic Syndromes (MDS) without Del(5q) and Unresponsive or Refractory to Erythropoiesis-Stimulating Agents (ESAs): Results from a Randomized Phase 3 Study (CC-5013-MDS-005)
Santini, Valeria, Almeida, Antonio, Giagounidis, Aristoteles, Gröpper, Stephanie, Jonasova, Anna, Vey, Norbert, Mufti, Ghulam J., Buckstein, Rena, Mittelman, Moshe, Platzbecker, Uwe, Shpilberg, Ofer, Ram, Ron, del Canizo, Consuelo, Gattermann, Norbert, Ozawa, Keiya, Zhong, Jim, Séguy, Francis, Hoenekopp, Albert, Beach, C.L., Fenaux, Pierre
Published in Blood (06.12.2014)
Published in Blood (06.12.2014)
Get full text
Journal Article
INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
Watts, Justin, Hunter, Anthony M., Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Reeves, Brandi, Vannucchi, Alessandro M., Chen, Xuejun, Seguy, Francis, Zhou, Feng, Zheng, Fred, Vachhani, Pankit
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
Oh, Stephen T., Gotlib, Jason, Mohan, Sanjay, Ali, Haris, Asatiani, Ekatherine, Seguy, Francis, Zhou, Feng, Verstovsek, Srdan
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Phase 1/2 study of the activin receptor-like kinase (ALK)-2 inhibitor zilurgisertib (INCB000928, LIMBER-104) as monotherapy or with ruxolitinib (RUX) in patients (pts) with anemia due to myelofibrosis (MF)
Bose, Prithviraj, Mohan, Sanjay, Oh, Stephen, Gotlib, Jason R., Ritchie, Ellen K., Shimomura, Taizo, Ali, Haris, Boyer, Francoise, Guglielmelli, Paola, Hunter, Anthony, Lamothe, Betty, Cui, Yi, Seguy, Francis, McBride, Amanda, Palandri, Francesca, Takeuchi, Masahiro, Kiladjian, Jean-Jacques
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Bromodomain and extra-terminal (BET) inhibitor INCB057643 (LIMBER-103) in patients (pts) with relapsed or refractory myelofibrosis (R/R MF) and other advanced myeloid neoplasms: A phase 1 study
Watts, Justin M., Hunter, Anthony, Iurlo, Alessandra, Xicoy, Blanca, Palandri, Francesca, Reeves, Brandi, Vannucchi, Alessandro M., Bose, Prithviraj, Diaz, Rosa Ayala, Halpern, Anna B., Chen, Xuejun, Seguy, Francis, Zhou, Feng, Zheng, Fred, Vachhani, Pankit
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)
Oh, Stephen T., Kiladjian, Jean-Jacques, Palandri, Francesca, Gotlib, Jason R., Mohan, Sanjay, Ali, Haris, Asatiani, Ekatherine, Seguy, Francis, Zhou, Feng, Verstovsek, Srdan
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
A Phase 1/2 Study of INCB000928 As Monotherapy or Combined with Ruxolitinib (RUX) in Patients (Pts) with Anemia Due to Myelofibrosis (MF)
Mohan, Sanjay R, Oh, Stephen T, Ali, Haris, Hunter, Anthony M., Palandri, Francesca, Lamothe, Betty, Cui, Yi, Seguy, Francis, McBride, Amanda, Savona, Michael Robert, Kiladjian, Jean-Jacques, Verstovsek, Srdan
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Phase 1/2 Study of the Activin Receptor-like Kinase-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104) As Monotherapy or with Ruxolitinib in Patients with Anemia Due to Myelofibrosis
Mohan, Sanjay, Oh, Stephen, Kiladjian, Jean-Jacques, Takeuchi, Masahiro, Gotlib, Jason, Ritchie, Ellen K., Shimomura, Taizo, Guglielmelli, Paola, Hunter, Anthony M., Palandri, Francesca, Boyer, Francoise, Rambaldi, Alessandro, Mori, Takehiko, Ito, Tomoki, Lamothe, Betty, Yang, Yan-Ou, Cui, Yi, Seguy, Francis, McBride, Amanda, Bose, Prithviraj
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article